21 December 2017 - Novartis’ Extavia is the only beta interferon being endorsed by the NICE as a cost-effective treatment option for multiple sclerosis.

In draft guidance, the Institute has recommended routine funding for the drug to treat adults with relapsing-remitting multiple sclerosis (MS) or secondary progressive multiple sclerosis with continued relapses.

Extavia is a beta 1b interferon and is self-injected every two days, that slows down damage to the nervous system caused by the condition and reduces the number of MS related relapses.

Read Pharma Times article